GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Inventories, Other

Viracta Therapeutics (FRA:RYI) Inventories, Other : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Viracta Therapeutics's other inventories for the quarter that ended in Mar. 2024 was €0.00 Mil.


Viracta Therapeutics Inventories, Other Historical Data

The historical data trend for Viracta Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Inventories, Other Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Other
- - - -

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Viracta Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Viracta Therapeutics (FRA:RYI) Business Description

Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.